Tech Company M&A Transactions
Delinia Acquisition
Delinia was acquired by Celgene. The transaction was announced on 1/26/2017. Purchase price was estimated to be $775 million.
Transaction Overview
Company Name
Acquired By
Announced On
1/26/2017
Transaction Type
M&A
Amount
$775,000,000
M&A Terms
Under the terms of the agreement, Celgene will make an initial payment of $300 million. Delinia shareholders will be eligible to receive up to an additional $475 million in contingent payments upon achievement of certain development, regulatory and commercial milestones.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
953 Indiana Street
San Francisco, CA 94107
USA
San Francisco, CA 94107
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Delinia is a biotechnology company developing novel therapeutics for the treatment of autoimmune diseases. Delinia's lead program is a molecule that potentiates and expands Regulatory T Cells (Tregs), powerful immune cells that are critical to maintaining self-tolerance and immune system homeostasis.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Saurabh Saha
Chief Scientific Officer
Jeffrey Greve
VP - Bus. Development
Lijun Wu
Browse more venture capital transactions:
Prev: 1/26/2017: CafeX Communications venture capital transaction
Next: 1/26/2017: Ring venture capital transaction
Share this article
News on VC Transactions
We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs